Patent details
301092
Product Name:
fedratinib, of een farmaceutisch aanvaardbaar zout ervan
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
Ok
Cancel
You have not selected any documents
Ok
Basic Information
Publication number:
301092
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP1278735
Status:
Expired Art. 14 (a) of the EC Regulations
Application number:
301092
Procedural language:
Dutch
First Applicant Residence Country:
Sweden (SE)
Marketing Authorization
Marketing Authorization Number:
EU/1/20/1514
Marketing Authorization Type:
EEA
Marketing Authorization Date:
09/02/2021
Marketing Authorization Country:
European Union (EU)
Dates
Filing date:
19/02/2021
First Marketing Authorization date:
09/02/2021
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
22/02/2021
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
26/02/2026
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:
Applicant/holder
From:
19/02/2021
Name:
AstraZeneca AB
Address:
-, 151 85 SÖDERTÄLJE, Sweden (SE)
Agent
1
Name:
dr. R.C. van Duijvenbode c.s.
From:
07/11/2025
Address:
NLO
Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:
2
Name:
ir. M.F.J.M. Ketelaars c.s.
From:
19/02/2021
Address:
NLO
Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:
07/11/2025
Publication
Bulletin
1
Bulletin Heading:
VRV
Journal edition number:
08/26
Publication date:
25/02/2026
Description:
Lapse or annulment
2
Bulletin Heading:
SPC
Journal edition number:
08/21
Publication date:
24/02/2021
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date
Document type
Document Description
Number of pages
File Type
20/09/2021
SPC Documents
Annex SPC
1
PDF
/9/9/8/2/5/0800652899/docs/301092_4_supplprotectioncertificate20210920115328904.pdf
20/09/2021
SPC Documents
Annex SPC
2
PDF
/9/9/8/2/5/0800652899/docs/301092_8_supplprotectioncertificate20210920115354229.pdf
20/09/2021
Incoming Correspondence Paper
Accompanying letter incoming document
5
PDF
/9/9/8/2/5/0800652899/docs/301092_9_incomingcorrespondencepaper20210920115707018.pdf
20/09/2021
SPC Documents
Annex SPC
10
PDF
/9/9/8/2/5/0800652899/docs/301092_12_supplprotectioncertificate20210920115259787.pdf
21/06/2021
Outgoing Correspondence
Letter to applicant
1
PDF
/9/9/8/2/5/0800652899/docs/301092_3_418298l173.pdf
18/06/2021
Incoming Correspondence Paper
Accompanying letter incoming document
1
PDF
/9/9/8/2/5/0800652899/docs/301092_0_incomingcorrespondencepaper20210618115331581.pdf
18/03/2021
Outgoing Correspondence
Letter to applicant
6
PDF
/9/9/8/2/5/0800652899/docs/301092_10_400007l173.pdf
22/02/2021
Outgoing Correspondence
Confirmation receipt request
1
PDF
/9/9/8/2/5/0800652899/docs/301092_1_395991l174.pdf
19/02/2021
SPC Documents
Annex SPC
2
PDF
/9/9/8/2/5/0800652899/docs/301092_2_supplprotectioncertificate20210222090058947.pdf
19/02/2021
SPC Documents
Marketing Authorization SPC
4
PDF
/9/9/8/2/5/0800652899/docs/301092_5_supplprotectioncertificate20210222085708161.pdf
19/02/2021
SPC Documents
Annex SPC
13
PDF
/9/9/8/2/5/0800652899/docs/301092_6_supplprotectioncertificate20210222090059020.pdf
19/02/2021
SPC Documents
Summary of the characteristics of the product
19
PDF
/9/9/8/2/5/0800652899/docs/301092_7_supplprotectioncertificate20210222090058862.pdf
19/02/2021
Application Form
First filed application form
2
PDF
/9/9/8/2/5/0800652899/docs/301092_11_applicationform20210222085436474.pdf